Using Selectivity to Optimize UHPLC Separations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Using Selectivity to Optimize UHPLC Separations
Ultrahigh pressure liquid chromatography maximizes efficiency, but, as defined by the resolution equation, the stationary phase is still a crucial consideration when attempting to resolve mixtures of compounds.


Pharmaceutical Technology



(AUTHOR)
Ultrahigh pressure liquid chromatography (UHPLC) has altered liquid separation procedures, but it has not changed the fundamental theory. Although UHPLC enables the use of sub-2-μm high-performance liquid chromatography packing materials, it is beneficial for a practicing chromatographer to consider the overall benefits and limitations of this technology. The author discusses the principles of chromatographic separations and explains how specific parameters such as stationary-phase selectivity and efficiency affect chromatographic resolution.

Background

Since the late 1960s, when modern HPLC became a viable tool for practicing chemists, continual advancements have been made in the technology. Considering analytical-scale HPLC columns in particular, over time there has been a movement from irregular to spherical particles, as well as an overall decrease in the size of the particles used in the packing material. For spherical silica particles, this shift has been from 10 μm to 5 μm, then to 3 μm, and most recently to sub-2-μm particles. When using a smaller particle-size packing material, it is possible to increase the efficiency, or number of theoretical plates, and expand the range of usable flow rates.


Figure 1: The resolution equation indicates that selectivity has the greatest influence on resolution.
However, this technique results in proportionately higher back pressure as liquid mobile phase is forced through a much more tightly packed bed. Conventional HPLC systems are capable of handling pressures as high as 5000 psi, which until recently limited the usable particle size to approximately 3 μm, depending on flow rate, mobile phase composition, and column temperature. The advent of UHPLC, which uses instrumentation capable of handling back pressures greater than 14,000 psi, makes using columns packed with sub-2-μm packings possible. With UHPLC, extremely fast and efficient liquid separations are possible.

Resolution

The overall goal in HPLC, and now UHPLC, is chromatographic resolution, whether between target analytes or between an analyte and the sample matrix. Considering, as a guideline, the fundamental relationships given in the resolution equation (see Figure 1), one can better understand the process of resolving mixtures. The resolution equation comprises three terms: selectivity (α – 1),





Figure 2: Efficiency, N, is inversely proportional to the particle diameter dp; therefore, as particle size decreases, efficiency increases.
and efficiency . (√N) Each of these terms is affected by the specific conditions chosen when developing an analytical method. How well one resolves the analytes and how quickly it is done depend upon the analyst's ability to control these three factors. Selectivity, which is governed predominantly by analyte interactions with both the stationary and mobile phases, is arguably the driving force behind separations because it affects resolution to the greatest degree. The smaller particles used in UHPLC primarily affect the efficiency, N, of the resolution equation. Although small particles can improve a separation, they are only one contributor toward the goal of resolution.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here